CLINICAL TRIALS AND OBSERVATIONS Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
نویسندگان
چکیده
1James P. Wilmot Cancer Center, University of Rochester, NY; 2Stanford University, CA; 3Cleveland Clinic, OH; 4Mayo Clinic, Rochester, MN; 5University of Nebraska, Omaha; 6Dana-Farber Cancer Institute, Boston, MA; 7University of California at Los Angeles; 8Emory University, Atlanta, GA; 9Cornell University, New York, NY; 10Indiana University, Indianapolis; 11Rush University, Chicago, IL; and 12Rigel Pharmaceuticals, South San Francisco, CA
منابع مشابه
Regular Article CLINICAL TRIALS AND OBSERVATIONS An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia
Spleen tyrosine kinase (Syk) is a cytoplasmic protein tyrosine kinase that is predominantly expressed in cells of hematopoietic lineage. Syk functions normally to couple activated immunoreceptors to downstream signaling pathways. Syk signaling elicits a range of diverse biologic functions, including cellular development, function, proliferation, differentiation, and adhesion. In a normal, resti...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: a meta-analysis of observational studies
Hematologic malignancies are a heterogeneous group of conditions with an unclear etiology. We hypothesized that diabetes mellitus type 2 is associated with increased risk of developing lymphoma, leukemia, and myeloma. A literature search identified 26 studies (13 casecontrol and 13 cohort studies) evaluating such an association. Outcome was calculated as the odds ratio (OR) using a random effec...
متن کاملDeveloping Drugs for Leukemia’s
At present, available therapies are only partially effective in patients with leukemia and the vast majority of patients cannot be cured with current treatment strategies. Hence, there is an obvious need to develop more specific and effective drugs for the treatment of these diseases. In the last twenty years, significant progress in molecular and cellular biology has resulted in a better chara...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients
Radioimmunotherapy of indolent nonHodgkin lymphoma (NHL) has achieved objective response rates in clinical trials comparable with standard rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy, but is relatively underused in routine practice. In this article, we report our clinical experience in 142 consecutive patients who received iodine-131 rituximab radioimm...
متن کاملInduction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents.
Phenylacetate (PA) and phenylbutyrate (PB) are aromatic fatty acids that are presently undergoing evaluation as potential antineoplastic agents. In vitro, PA and PB cause differentiation or growth inhibition of malignant cells. Clinical trials of these drugs as single agents indicate that they are not myelosuppressive; therefore, combinations with other chemotherapy agents may be possible. The ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2010